$152.88 Million in Sales Expected for NextGen Healthcare, Inc. (NASDAQ:NXGN) This Quarter

Wall Street brokerages expect NextGen Healthcare, Inc. (NASDAQ:NXGNGet Rating) to announce $152.88 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for NextGen Healthcare’s earnings, with estimates ranging from $152.54 million to $153.50 million. NextGen Healthcare posted sales of $146.08 million during the same quarter last year, which suggests a positive year over year growth rate of 4.7%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that NextGen Healthcare will report full year sales of $633.26 million for the current fiscal year, with estimates ranging from $628.27 million to $636.10 million. For the next year, analysts anticipate that the business will report sales of $670.55 million, with estimates ranging from $644.76 million to $684.90 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow NextGen Healthcare.

NextGen Healthcare (NASDAQ:NXGNGet Rating) last posted its earnings results on Tuesday, May 17th. The company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. NextGen Healthcare had a return on equity of 10.11% and a net margin of 0.27%. The company had revenue of $151.26 million for the quarter, compared to the consensus estimate of $150.07 million. During the same quarter in the prior year, the company earned $0.13 earnings per share. NextGen Healthcare’s revenue was up 4.9% on a year-over-year basis.

A number of research firms have weighed in on NXGN. Guggenheim raised NextGen Healthcare from a “neutral” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Friday, May 6th. StockNews.com assumed coverage on NextGen Healthcare in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Finally, Zacks Investment Research cut NextGen Healthcare from a “hold” rating to a “sell” rating and set a $21.00 price target for the company. in a research report on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $22.17.

In related news, Director Craig A. Barbarosh sold 3,500 shares of the stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $21.27, for a total transaction of $74,445.00. Following the completion of the sale, the director now owns 74,683 shares in the company, valued at $1,588,507.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO David A. Metcalfe sold 33,838 shares of the stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $20.11, for a total value of $680,482.18. Following the sale, the chief technology officer now owns 155,013 shares of the company’s stock, valued at approximately $3,117,311.43. The disclosure for this sale can be found here. In the last 90 days, insiders sold 80,926 shares of company stock valued at $1,620,410. Company insiders own 18.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in NXGN. Nisa Investment Advisors LLC bought a new position in NextGen Healthcare during the first quarter valued at approximately $63,000. Captrust Financial Advisors boosted its stake in NextGen Healthcare by 61.5% during the first quarter. Captrust Financial Advisors now owns 4,255 shares of the company’s stock valued at $89,000 after buying an additional 1,620 shares during the last quarter. Advisor Group Holdings Inc. boosted its stake in NextGen Healthcare by 12.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 5,127 shares of the company’s stock valued at $92,000 after buying an additional 548 shares during the last quarter. Lazard Asset Management LLC boosted its stake in NextGen Healthcare by 66.9% during the fourth quarter. Lazard Asset Management LLC now owns 5,231 shares of the company’s stock valued at $93,000 after buying an additional 2,097 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in NextGen Healthcare by 214.9% during the second quarter. Royal Bank of Canada now owns 5,617 shares of the company’s stock valued at $93,000 after buying an additional 3,833 shares during the last quarter. 71.15% of the stock is owned by institutional investors.

NXGN stock opened at $18.12 on Thursday. NextGen Healthcare has a fifty-two week low of $13.64 and a fifty-two week high of $21.87. The business’s 50-day moving average is $19.86 and its two-hundred day moving average is $18.78. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 604.20 and a beta of 1.17.

About NextGen Healthcare (Get Rating)

NextGen Healthcare, Inc provides software and services for ambulatory healthcare services in the United States. The company offers patient engagement solutions, comprising of NextGen PxP Portal, NextGen Patient Self Scheduling, NextGen Pay, and NextGen Virtual Visits; clinical care solutions, including NextGen Enterprise HER, NextGen Mobile, NextGen Office, NextGen Behavioral Health Suite, NextGen Orthopedic Suite, and QSIDental Web and QSIDental PM; and financial management solutions, such as NextGen Enterprise PM and NextGen Clearinghouse Solutions.

Featured Articles

Get a free copy of the Zacks research report on NextGen Healthcare (NXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NextGen Healthcare (NASDAQ:NXGN)

Receive News & Ratings for NextGen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextGen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.